Media headlines about Axsome Therapeutics (NASDAQ:AXSM) have been trending somewhat positive on Saturday, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Axsome Therapeutics earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.0370915008299 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Axsome Therapeutics (NASDAQ:AXSM) traded up $0.10 during mid-day trading on Friday, hitting $2.70. 328,114 shares of the company’s stock traded hands, compared to its average volume of 565,443. The stock has a market capitalization of $71.36 and a price-to-earnings ratio of -1.99. Axsome Therapeutics has a 1-year low of $2.45 and a 1-year high of $6.45. The company has a current ratio of 3.86, a quick ratio of 3.86 and a debt-to-equity ratio of 0.44.
Several analysts have commented on AXSM shares. ValuEngine raised shares of Axsome Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Zacks Investment Research raised shares of Axsome Therapeutics from a “hold” rating to a “buy” rating and set a $6.50 price target for the company in a research report on Monday, January 1st. Finally, Cantor Fitzgerald set a $13.00 price target on shares of Axsome Therapeutics and gave the company a “buy” rating in a research report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $16.90.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Axsome Therapeutics (AXSM) Stock Price” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/17/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-axsome-therapeutics-axsm-stock-price.html.
About Axsome Therapeutics
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.